Search Results - "Rubbert-Roth, Andrea"

Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 216 from the SELECT-CHOICE Study.

Authors: Rubbert-Roth, Andrea Kato, Koji Haraoui, Boulos et al.

Source: Rheumatology & Therapy. Oct2024, Vol. 11 Issue 5, p1197-1215. 19p.

Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis.

Authors: Rubbert-Roth, Andrea Kakehasi, Adriana M. Takeuchi, Tsutomu et al.

Source: Rheumatology & Therapy. Feb2024, Vol. 11 Issue 1, p97-112. 16p.

Golimumab for the Treatment of Rheumatoid Arthritis: A Narrative Review of Pivotal Randomized Trials and Real-World Studies.

Authors: Kiltz, Uta Chen, Yi-Ming Rubbert-Roth, Andrea et al.

Source: Rheumatology & Therapy. May2026, p1-32. 32p.

Bei Diagnostik und medikamentöser Therapie der entzündlichen Arthritiden gibt es geschlechtsspezifische Unterschiede.

Authors: Rubbert-Roth, Andrea¹ (AUTHOR)

Source: Kompass Autoimmun. 2023, Vol. 5 Issue 3, p101-103. 3p.

Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial.

Authors: Rech, Juergen Tascilar, Koray Hagen, Melanie et al.

Source: Lancet. Mar2024, Vol. 403 Issue 10429, p850-859. 10p.

Subjects: Rheumatoid arthritis, Abatacept, Joint pain, Tenosynovitis, Inflammation, Community centers, Synovitis

A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases.

Authors: Rubbert-Roth, Andrea Furst, Daniel E. Nebesky, Jan Michael et al.

Source: Rheumatology & Therapy. Jun2018, Vol. 5 Issue 1, p21-42. 22p.

Persistence and effectiveness of upadacitinib and TNFi for rheumatoid arthritis using pooled data from Canadian and Swiss registries.

Authors: Choquette, Denis Finckh, Axel Rubbert-Roth, Andrea et al.

Source: Rheumatology. Jun2026, Vol. 65 Issue 6, p1-10. 10p.

Effect of disease duration and other characteristics on efficacy outcomes in clinical trials of tocilizumab for rheumatoid arthritis.

Authors: Rubbert-Roth, Andrea Aletaha, Daniel Devenport, Jenny et al.

Source: Rheumatology. Feb2021, Vol. 60 Issue 2, p682-691. 10p.

Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis.

Authors: Rubbert-Roth, Andrea Enejosa, Jeffrey Pangan, Aileen L. et al.

Source: New England Journal of Medicine. 10/15/2020, Vol. 383 Issue 16, p1511-1521. 11p.

Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials.

Authors: Burmester, Gerd R. Stigler, Jayne Rubbert-Roth, Andrea et al.

Source: Rheumatology & Therapy. Jun2024, Vol. 11 Issue 3, p737-753. 17p.

Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.

Authors: Genovese, Mark C. Fleischmann, Roy Combe, Bernard et al.

Source: Lancet. 6/23/2018, Vol. 391 Issue 10139, p2513-2524. 12p.

Subjects: Rheumatoid arthritis treatment, Medication safety, Drug efficacy, Randomized controlled trials, Placebos, Antirheumatic agents, Comparative studies, Controlled release preparations, Dose-effect relationship in pharmacology, Research methodology, Medical cooperation, Methotrexate, Research, Rheumatoid arthritis, Evaluation research, Blind experiment, Severity of illness index

TNF inhibitors in rheumatoid arthritis and spondyloarthritis: Are they the same?

Authors: Rubbert-Roth, Andrea Atzeni, Fabiola Masala, Ignazio Francesco et al.

Source: Autoimmunity Reviews. Jan2018, Vol. 17 Issue 1, p24-28. 5p.

To switch or not to switch after a poor response to a TNFα blocker? It is not only a matter of ACR20 OR ACR50

Authors: Buch, Maya H. Rubbert-Roth, Andrea Ferraccioli, Gianfranco

Source: Autoimmunity Reviews. Jun2012, Vol. 11 Issue 8, p558-562. 5p.

Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR).

Authors: Rubbert-Roth, Andrea Tak, Paul P. Zerbini, Cristiano et al.

Source: Rheumatology. Sep2010, Vol. 49 Issue 9, p1683-1693. 11p. 2 Diagrams, 4 Charts, 3 Graphs.

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

Authors: Smolen JS Beaulieu A Rubbert-Roth A et al.

Source: Lancet. 3/22/2008, Vol. 371 Issue 9617, p987-997. 11p.

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

Authors: Beaulieu, Andre Rubbert-Roth, Andrea Ramos-Remus, Cesar et al.

Source: Lancet. 3/22/2008, Vol. 371 Issue 9617, p987-997. 11p.

Subjects: Rheumatoid arthritis, Autoimmune diseases, Arthritis patients, Drug efficacy, Interleukin-6, Interleukins, Patients

Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis.

Authors: Rubbert-Roth, Andrea Xavier, Ricardo M.

Source: New England Journal of Medicine. 1/7/2021, Vol. 384 Issue 1, p83-84. 2p.

Failure of anti-TNF treatment in patients with rheumatoid arthritis: The pros and cons of the early use of alternative biological agents.

Authors: Rubbert-Roth, Andrea Szabó, Melinda Zsuzsanna Kedves, Melinda et al.

Source: Autoimmunity Reviews. Dec2019, Vol. 18 Issue 12, pN.PAG-N.PAG. 1p.

Worse cardiovascular and renal outcome in male SLE patients.

Authors: Mihailovic, Jelena Ribi, Camillo Chizzolini, Carlo et al.

Source: Scientific Reports. 10/30/2023, Vol. 13 Issue 1, p1-12. 12p.

Patient Disease Trajectories in Rheumatoid Arthritis Patients Treated with Baricitinib 4-mg in Four Phase 3 Clinical Studies.

Authors: Taylor, Peter C. Chen, Yun-Fei Pope, Janet et al.

Source: Rheumatology & Therapy. Apr2023, Vol. 10 Issue 2, p463-476. 14p.